A year ago, they were trading at $1.04. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VVUS at https://www.zacks.com/ap/VVUS
Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc.'s stock finished Thursday's session 2.95% lower at $127.24 with a total trading volume of 1.37 million shares. Over the last month and the previous three months, the Company's shares have ...
Le Lézard · 11mon
The average investor's response to VVUS's undesirable statistics is to drop the stock or even short it (you do not short a $2 stock without a good reason). But in this article, I wish to offer a contrarian view, one that seeks VVUS as undervalued.
But, with VVUS stock trading at $5.21 per share, VIVUS is a $538 million organization with little else on its product menu besides its diet pills. That’s still well shy of the $1.8 billion in annual sales some analysts were batting around shortly after ...
Campbell, CA-based VIVUS, Inc. VVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs. The company's portfolio comprises two drugs, Qsymia for chronic weight management and ...
In that article we said the following regarding VVUS stock: VVUS is currently range-bound between the 50-day and 200-day exponential moving averages. If a run-up in VVUS is to occur ahead of the EU approval decision, look for the stock price to close above ...
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VVUS at https://www.zacks.com/ap/VVUS Keywords: Vivus, Earnings Report
Campbell, CA-based VIVUS, Inc. VVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs. The company's portfolio comprises two drugs, Qsymia for chronic weight management and ...